Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=760 Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Gout
Primary: Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) — 53; 62; 21 Percentage of subjects — p=<0.001
Phase 3 N=122 A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)
Hypertension
Primary: Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 — -0.2; -5.2; -6.4; -8.5 mm Hg
Phase 3 N=91 Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration — 0.07; 0.05; 0.06 Liter — p=0.871
Phase 3 N=1,268 Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
Migraine Headache
Primary: Pain Relief at 2 Hours After Dose — 99; 258; 239; 64 Participants
Phase 3 N=868 The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
Psoriasis
Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16. — 0.78; 0.42 Proportion of participants — p=<0.001
Phase 3 N=637 A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive
Rheumatoid Arthritis
Primary: Number of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24 — 47; 52; 64; 58 Participants — p=0.053
Phase 3 N=356 A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
Spondylitis, Ankylosing
Primary: Assessment in Ankylosing Spondylitis 20 Responders at Week 14 — 17; 82; 84; 166 Participants — p=<0.001
Phase 3 N=1,042 Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months) — 416; 417 Participants — p=<0.001
Phase 3 N=520 Initial Combination With Pioglitazone Study (0431-064)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -2.38; -1.49 Percent — p=<0.001
Phase 3 N=679 TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
Migraine, Without Aura
Primary: Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose. — 25; 64; 20; 54 Participants — p=<0.001
Phase 3 N=546 Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
Haemophilus Influenzae Type B · Hepatitis B
Primary: The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose. — 230; 226 Participants
Phase 3 N=1,312 Dose Confirmation Efficacy Study (V260-007)
Rotavirus Infections
Primary: Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose. — 15; 54…
Phase 3 N=90 Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
Phenylketonurias
Primary: Amount of Dietary Supplemented Phenylalanine (Phe)Tolerated in Children With Phenylketonuria — 20.9; 2.9 mg/kg/day — p=<0.001
Phase 3 N=277 Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
Hepatitis B Virus Infection
Primary: The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7 — 49; 64 Participants